An economic perspective on childhood obesity: Recent findings on cost of illness and cost effectiveness of interventions

Nutrition ◽  
2012 ◽  
Vol 28 (9) ◽  
pp. 829-839 ◽  
Author(s):  
Jürgen John ◽  
Silke B. Wolfenstetter ◽  
Christina M. Wenig
Keyword(s):  
Cost Effectiveness ◽  
Childhood Obesity ◽  
Cost Of Illness ◽  
Economic Perspective

Cost-of-illness studies and cost-effectiveness analyses in eating disorders: A systematic review

2012 ◽  
Vol 45 (4) ◽  
pp. 476-491 ◽  
Author(s):  
Nina Stuhldreher ◽  
Alexander Konnopka ◽  
Beate Wild ◽  
Wolfgang Herzog ◽  
Stephan Zipfel ◽  
...  
Keyword(s):  
Systematic Review ◽  
Eating Disorders ◽  
Cost Effectiveness ◽  
Cost Of Illness ◽  
Cost Of Illness Studies

An Economic Perspective on Childhood Obesity

2015 ◽  
pp. 148-159
Author(s):  
Christina M. Teuner ◽  
Jürgen John ◽  
Silke B. Wolfenstetter ◽  
Rolf Holle
Keyword(s):  
Childhood Obesity ◽  
Economic Perspective

Cost-effectiveness of AI in medicine from a clinical, technical, and economic perspective: A scoping review and a framework of analysis (Preprint)

2021 ◽  
Author(s):  
Jesus Gomez Rossi ◽  
Ben Feldberg ◽  
Joachim Krois ◽  
Falk Schwendicke
Keyword(s):  
Artificial Intelligence ◽  
Cost Effectiveness ◽  
Scientific Literature ◽  
Economic Aspects ◽  
Inclusion Criteria ◽  
Economic Perspective ◽  
Health Policy Analysis ◽  
The Cost ◽  
The Relationship ◽  
Potential Use

BACKGROUND Research and Development (R&D) of Artificial Intelligence (AI) in medicine involve clinical, technical and economic aspects. Better understanding the relationship between these dimensions seems necessary to coordinate efforts of R&D among stakeholders. OBJECTIVE To assess systematically existing literature on the cost-effectiveness of Artificial Intelligence (AI) from a clinical, technical and economic perspective. METHODS A systematic literature review was conducted to study the cost-effectiveness of AI solutions and summarised within a scoping framework of health policy analysis developed to study clinical, technical and economic dimensions. RESULTS Of the 4820 eligible studies, 13 met the inclusion criteria. Internal medicine and emergency medicine were the most studied clinical disciplines. Technical R&D aspects have not been uniformly disclosed in the studies we analysed. Monetisation aspects such as payment models assumed have not been reported in the majority of cases. CONCLUSIONS Existing scientific literature on the cost-effectiveness of AI currently does not allow to draw conclusive recommendations. Further research and improved reporting on technical and economic aspects seem necessary to assess potential use-cases of this technology, as well as to secure reproducibility of results. CLINICALTRIAL Not applicable

Cost‐Effectiveness of Water Promotion Strategies in Schools for Preventing Childhood Obesity and Increasing Water Intake

Obesity ◽  
2019 ◽  
Vol 27 (12) ◽  
pp. 2037-2045 ◽  
Author(s):  
Erica L. Kenney ◽  
Angie L. Cradock ◽  
Michael W. Long ◽  
Jessica L. Barrett ◽  
Catherine M. Giles ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Childhood Obesity ◽  
Water Intake ◽  
Promotion Strategies

Cost-of-illness and economic evaluations in axial spondyloarthritis

2016 ◽  
Author(s):  
Annelies Boonen
Keyword(s):  
Cost Effectiveness ◽  
Cost Of Illness ◽  
Axial Spondyloarthritis ◽  
Economic Evaluations ◽  
Low Back ◽  
Quality Adjusted Life Years ◽  
Life Years ◽  
Methodological Principles ◽  
The Cost ◽  
Quality Adjusted Life

Consideration of costs and budgets plays an increasingly important role in decisions on access to innovative technologies. When clinicians want to influence such decisions, it is essential to understand the information on the burden of the disease and the evidence on cost-effectiveness of technologies. This chapter provides guidance to understanding the key methodological principles of economic evaluations, and describes available evidence on these issues in axial spondyloarthritis (axSpA). In the prebiologics era, the cost-of-illness for society of ankylosing spondylitis was slightly lower than for rheumatoid arthritis, and substantially lower than chronic low back pain. Cost of sick leave and work disability accounted for up to 75% of total cost-of-illness. Treatment with biologics increased cost-of-illness substantially, but the important gain in quality-adjusted life years resulted in acceptable cost-effectiveness in patients with active disease. There remains a gap in knowledge about the cost-effectiveness of diagnosing and treating axSpA earlier.

scholarly journals Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review

2019 ◽  
Vol 10 ◽  
pp. 204201881982821 ◽  
Author(s):  
Enrique Grande ◽  
Ángel Díaz ◽  
Carlos López ◽  
Javier Munarriz ◽  
Juan-José Reina ◽  
...  
Keyword(s):  
Systematic Review ◽  
Economic Evaluation ◽  
Cost Effectiveness ◽  
Adverse Events ◽  
Resource Utilization ◽  
Neuroendocrine Tumors ◽  
Cost Of Illness ◽  
Budget Impact ◽  
The United States ◽  
Economic Evaluations

Background: Despite current interest, enthusiasm and progress in the development of therapies for gastroenteropancreatic (GEP) neuroendocrine tumors (NETs), there are substantial gaps in the published literature regarding cost-of-illness analyses, economic evaluation and budget impact analyses. Compounding the issue is that data on resource utilization and cost-effectiveness of different diagnostic and therapeutic modalities for GEP-NETs are scarce. Methods: A systematic review on the economic impact of GEP-NETs was carried out using four databases: EMBASE, PubMed, the National Health Service Economic Evaluation Database and Cochrane review. Fully published articles from January 2000 to May 2017, in English and Spanish, were included. All articles that satisfied the inclusion criteria were included in the systematic review; summary descriptive statistics were used to describe the methodological characteristics. Results: The 14 studies selected included cost-of-illness analyses ( n = 4), economic evaluations ( n = 7) and budget impact analyses ( n = 3). Almost all studies were performed in the United States. Healthcare costs for patients with NETs included medication, outpatient visits, hospitalizations, and check-ups/tests. Reducing adverse events is an area where cost savings could be achieved; however, there was not enough evidence on the cost impact of adverse events. Conclusion: There is a lack of data related to resource utilization in the field of GEP-NETs. Therefore, cost-effectiveness and budget impact studies of existing and emerging treatments are urgently needed to help the decision-making process for patients with NETs.

scholarly journals PIH25 Cost-Effectiveness of Interventions Against Childhood Obesity

2011 ◽  
Vol 14 (7) ◽  
pp. A402
Author(s):  
J.M. Ramos-Goñi ◽  
C. Valcárcel-Nazco ◽  
I. Castilla-Rodríguez
Keyword(s):  
Cost Effectiveness ◽  
Childhood Obesity

scholarly journals Cost-Effectiveness of a Clinical Childhood Obesity Intervention

PEDIATRICS ◽  
2017 ◽  
Vol 140 (5) ◽  
pp. e20162998 ◽  
Author(s):  
Mona Sharifi ◽  
Calvin Franz ◽  
Christine M. Horan ◽  
Catherine M. Giles ◽  
Michael W. Long ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Childhood Obesity ◽  
Obesity Intervention

scholarly journals The cost of illness attributable to diabetic foot and cost-effectiveness of secondary prevention in Peru

2015 ◽  
Vol 15 (1) ◽  
Author(s):  
María Kathia Cárdenas ◽  
Andrew J. Mirelman ◽  
Cooper J. Galvin ◽  
María Lazo-Porras ◽  
Miguel Pinto ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Secondary Prevention ◽  
Cost Of Illness ◽  
Diabetic Foot ◽  
The Cost
Sign in / Sign up

Export Citation Format

Share Document